Main contents starts here
June 5, 2012
CHICAGO, Illinois, June 4, 2012 – Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated results from a Phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA). These data were presented in a poster discussion session at the annual meeting of the American Society of Clinical Oncology (ASCO), held June 1-5 in Chicago, Illinois.
“Non-metastatic castration resistant prostate cancer is an area of unmet need, and therapies that reduce PSA without the need for concomitant corticosteroids are of particular interest in these earlier lines of prostate cancer treatment,” said Daniel George, M.D., Duke University Medical Center.
“We are encouraged by the results with orteronel in non-metastatic prostate cancer,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium. “These data support the continued evaluation of orteronel in a steroid free regimen.”
The primary objective of this study was to determine the percentage of patients achieving a PSA reduction to ≤ 0.2 ng/mL (undetectable levels). Patients with PSA values of 0.2ng/mL or less have been shown to have a greater survival advantage. Secondary objectives were to determine the safety of orteronel, PSA response rates at 3 months and 6 months (decline in PSA of ≥ 90 percent, ≥ 50 percent and/or ≥ 30 percent), the percentage of patients achieving a PSA reduction to ≤ 0.2 ng/mL after 6 months, time to PSA progression, time to metastases, duration of progression-free survival, and changes in endocrine markers.
Results from the study of 39 patients, which were presented by Dr. George, showed:
Eligible pts had nmCRPC with PSA ≥ 2 ng/mL (PSA ≥ 8 ng/mL if doubling time > 8 mo), and surgical/medical castration, with testosterone (T) < 50 ng/dL. Prior chemotherapy or ketoconazole, and concomitant corticosteroids were excluded. Starting dose of TAK-700 was 300 mg BID and continued until PSA progression, metastases, or unacceptable toxicity.
# # #
Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/InTheNews.aspx.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Skip sub navigation